Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

napsr Press Releases

  + XML/RSS  



By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

By NAPSRx
With the worst Ebola outbreak in history, the virus continues to spread and now there's a confirmed case in the United States. It’s no surprise the experimental ZMapp cocktail has been at the center of discussion as the number one treatment option.

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

By NAPSRx
The U.S Food and Drug Administration (FDA) has approved the inhalation mist version of Boehringer Ingelheim’s Spiriva® Respimat®  (tiotropium bromide) to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD), including...

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) administered as a oral, selective inhibitor of phosphodiesterase 4 (PDE40 to treat  patients with with moderate to severe plaque psoriasis for whom phototherapy or...

By NAPSRx
The FDA’s Fast Track program has been implemented to accelerate the development and review of drugs to treat serious conditions and fill an unmet medical need

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

All Press Releases

By NAPSRx
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.

By NAPSRx
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...

By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

By NAPSRx
The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.

By NAPSRx
According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023.

By NAPSRx
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...

By NAPSRx
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.

By NAPSRx
Actavis will acquire Durata’s novel antibiotic DALVANCE - the first and only IV antibiotic approved for the treatment of ABSSSI.

By NAPSRx
Novartis and Bristol-Myers Squibb will join forces on a clinical collaboration which involves evaluating the safety, tolerability and preliminary efficacy of Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational...

By NAPSRx
In an effort to boost research and development for therapies and products to treat rare diseases, the U.S.

By NAPSRx
With the worst Ebola outbreak in history, the virus continues to spread and now there's a confirmed case in the United States. It’s no surprise the experimental ZMapp cocktail has been at the center of discussion as the number one treatment option.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) joins the list of major pharmaceutical giants acquiring smaller biotech/biopharma firms encompassing a growing trend of big pharma’s initiative to further research and development of specific drugs to treat rare...

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

By NAPSRx
The U.S Food and Drug Administration (FDA) has approved the inhalation mist version of Boehringer Ingelheim’s Spiriva® Respimat®  (tiotropium bromide) to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD), including...

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) administered as a oral, selective inhibitor of phosphodiesterase 4 (PDE40 to treat  patients with with moderate to severe plaque psoriasis for whom phototherapy or...

By NAPSRx
The FDA’s Fast Track program has been implemented to accelerate the development and review of drugs to treat serious conditions and fill an unmet medical need

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

By NAPSRx
Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

By NAPSRx
ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.

By NAPSRx
Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
Cerdelga™ is the only first-line oral therapy approved to treat adults with Type 1 Gaucher Disease, a rare genetic disorder that affects specific cells and organs in the body.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

By NAPSRx
Actavis plc (NYSE: ACT) is a specialty pharmaceutical company specializing in developing, manufacturing and commercializing generic drugs and branded pharmaceutical products.

By NAPSRx
Teva is a manufacturer of generics and specialty pharmaceuticals and is currently the world leader in generic drug sales.

By NAPSRx
The approval of Stiverdi Respimat is another great achievement for Boehringer Ingelheim as they continuously expand on their respiratory product pipeline.

By NAPSRx
AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

By NAPSRx
Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.

By NAPSRx
IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

By NAPSRx
Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.

By NAPSRx
Based on industry analysis, the emerging healthcare market will experience a continuous growth in the pharmaceutical sales sector.



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share